ArticleThe Canadian veterinary journal = La revue veterinaire canadienne2026
Medical management of multifocal immune-mediated punctate keratitis in 3 dogs: A case series.
Article in The Canadian veterinary journal = La revue veterinaire canadienne, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issuedErratum.2026
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multifocal immune-mediated punctate keratitis (MIPK) is an uncommon corneal disease in dogs characterized by multifocal anterior stromal opacities with fluorescein retention that may not respond to conventional therapy for superficial corneal ulcers. Clinical decision-making is challenging because concurrent corneal epithelial defects are considered a relative contraindication to topical immunosuppressive therapy. Three dogs were presented with multifocal punctate corneal opacities and positive fluorescein staining; MIPK was diagnosed based on characteristic clinical findings and exclusion of infectious causes. All 3 dogs received topical cyclosporine as the primary immunomodulatory agent; 2 dogs were subsequently treated with topical corticosteroids after infectious and non-immune-mediated causes were excluded, and 1 dog initially received a topical nonsteroidal anti-inflammatory drug that was subsequently replaced with a topical corticosteroid. Adjunctive therapies included temporary tarsorrhaphy in 1 dog and bandage contact lens in another. Corneal epithelial defects and stromal opacities improved within 1 to 5 wk and no clinical recurrence was observed during follow-up periods of 4 to 14 wk, despite tapering of anti-inflammatory therapy. These cases support early initiation of topical cyclosporine combined with carefully selected anti-inflammatory agents for canine MIPK, despite the presence of superficial corneal ulceration, provided infectious or non-immune-mediated causes have been thoroughly excluded. Key clinical message: Early initiation of topical cyclosporine combined with carefully selected anti-inflammatory agents effectively managed canine MIPK, even in the presence of superficial corneal ulceration.
Indexed as
Identifiers
42368697PMC13295205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.